The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2018.00160/full |
| _version_ | 1828341027762601984 |
|---|---|
| author | Devinder S. Dhindsa Pratik B. Sandesara Michael D. Shapiro |
| author_facet | Devinder S. Dhindsa Pratik B. Sandesara Michael D. Shapiro |
| author_sort | Devinder S. Dhindsa |
| collection | DOAJ |
| description | Diabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular, diabetes care and management of its attendant cardiovascular risk is now being revolutionized with the development and provision of the SGLT-2 inhibitors and GLP1-receptor agonists. Given the exciting data with these new classes of diabetes therapeutics, there is a clear need to improve education and utilization of these evidence-based medications across a wide spectrum of clinicians, including cardiologists. The aim of this review is to familiarize the cardiovascular specialist with the benefits and harms of the most commonly used oral anti- hyperglycemic medications, with an emphasis on SGLT-2 inhibitors and GLP-1 receptor agonists. |
| first_indexed | 2024-04-13T23:06:20Z |
| format | Article |
| id | doaj.art-943187abdd7f488ea3f804c3d9cf9b44 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-13T23:06:20Z |
| publishDate | 2018-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-943187abdd7f488ea3f804c3d9cf9b442022-12-22T02:25:40ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2018-11-01510.3389/fcvm.2018.00160426148The Intersection of Diabetes and Cardiovascular Disease—A Focus on New TherapiesDevinder S. Dhindsa0Pratik B. Sandesara1Michael D. Shapiro2Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United StatesDivision of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United StatesCenter for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, United StatesDiabetes is a leading cause of cardiovascular disease and its associated morbidity. While the medical community has had access to numerous glucose lowering therapies over the last decades, it was not until recently that newer agents demonstrated improvement in cardiovascular outcomes. In particular, diabetes care and management of its attendant cardiovascular risk is now being revolutionized with the development and provision of the SGLT-2 inhibitors and GLP1-receptor agonists. Given the exciting data with these new classes of diabetes therapeutics, there is a clear need to improve education and utilization of these evidence-based medications across a wide spectrum of clinicians, including cardiologists. The aim of this review is to familiarize the cardiovascular specialist with the benefits and harms of the most commonly used oral anti- hyperglycemic medications, with an emphasis on SGLT-2 inhibitors and GLP-1 receptor agonists.https://www.frontiersin.org/article/10.3389/fcvm.2018.00160/fulldiabetescardiovascular diseasecardiovascular outcomes trialsSGLT-2 inhibitorsGLP1-receptor agonists |
| spellingShingle | Devinder S. Dhindsa Pratik B. Sandesara Michael D. Shapiro The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies Frontiers in Cardiovascular Medicine diabetes cardiovascular disease cardiovascular outcomes trials SGLT-2 inhibitors GLP1-receptor agonists |
| title | The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies |
| title_full | The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies |
| title_fullStr | The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies |
| title_full_unstemmed | The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies |
| title_short | The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies |
| title_sort | intersection of diabetes and cardiovascular disease a focus on new therapies |
| topic | diabetes cardiovascular disease cardiovascular outcomes trials SGLT-2 inhibitors GLP1-receptor agonists |
| url | https://www.frontiersin.org/article/10.3389/fcvm.2018.00160/full |
| work_keys_str_mv | AT devindersdhindsa theintersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies AT pratikbsandesara theintersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies AT michaeldshapiro theintersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies AT devindersdhindsa intersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies AT pratikbsandesara intersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies AT michaeldshapiro intersectionofdiabetesandcardiovasculardiseaseafocusonnewtherapies |